20M Stock Chart & Stats
€0.04
>-€0.01(-2.27%)
At close: 4:00 PM EDT
€0.04
>-€0.01(-2.27%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.00
Market Cap
€17.23M
Enterprise Value€31.73M
Total Cash (Recent Filing)€1.42M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-15.87
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding457,002,000
10 Day Avg. Volume15
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-199.92
Price to Sales (P/S)433.67
P/FCF Ratio-13.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageReported zero debt reduces the company’s direct interest burden and lowers conventional leverage risk over the next several quarters. This provides some financial flexibility relative to a similarly loss-making business with significant borrowings, although equity volatility remains a concern.
Gross Margin And Revenue GrowthThe company is generating positive gross profit and modest TTM revenue growth despite its very small scale. If maintained, this combination could provide a foundation for operating improvement as commercialization develops, though current revenue remains too limited to support profitability.
Multi-Application Technology FocusA platform approach spanning consumer health and pharmaceutical-oriented applications gives the company multiple potential avenues for product development and commercialization. Broader application scope may support future opportunity diversification, provided the technologies achieve adoption and commercial traction.
Bears Say
Minimal Revenue ScaleRevenue remains far too small to absorb the company’s operating structure, leaving reported losses extremely disproportionate to sales. This weak scale limits operating leverage and makes future financial improvement dependent on substantial commercialization progress rather than incremental cost efficiencies.
Persistent Cash BurnOngoing negative operating and free cash flow shows that the business is not self-funding and continues to consume cash. Sustained burn can constrain investment in development and commercialization while increasing reliance on external financing to maintain operations over the medium term.
Equity And Funding VolatilityLarge equity swings, including a period of negative equity, indicate an unstable capital base despite zero reported debt. Continued financing dependence can create dilution or balance-sheet pressure and may limit management’s ability to pursue long-term development without additional capital.
Mountain Valley MD News
20M FAQ
What was Mountain Valley MD’s price range in the past 12 months?
Mountain Valley MD lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Mountain Valley MD’s market cap?
Mountain Valley MD’s market cap is €17.23M.
When is Mountain Valley MD’s upcoming earnings report date?
Mountain Valley MD’s upcoming earnings report date is Nov 26, 2026 which is in 43 days.
How were Mountain Valley MD’s earnings last quarter?
Mountain Valley MD released its earnings results on Jul 28, 2026. The company reported -€0.002 earnings per share for the quarter.
Is Mountain Valley MD overvalued?
According to Wall Street analysts Mountain Valley MD’s price is currently Overvalued.
Does Mountain Valley MD pay dividends?
Mountain Valley MD does not currently pay dividends.
What is Mountain Valley MD’s EPS estimate?
Mountain Valley MD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mountain Valley MD have?
Mountain Valley MD has 457,002,000 shares outstanding.
What happened to Mountain Valley MD’s price movement after its last earnings report?
Mountain Valley MD reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went up 16.667%.
Which hedge fund is a major shareholder of Mountain Valley MD?
Currently, no hedge funds are holding shares in DE:20M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mountain Valley MD
The More Life Co. Corp. is a biotechnology company, which engages in the provision of solutions to optimize human, animal, and plant health. Its patented technologies includes Quicksome™ and Quicksol™. The Quicksome™ patented technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into product formats that, if successfully commercialized, could enhance the efficacy of molecule delivery across a variety of nutraceutical product applications. The Quicksol™ patented is a solubilization technology, which has been developed to provide solubilized drug delivery options. The company was founded on March 8, 2005 and is headquartered in Vaughan, Canada.